Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients With Acute Myeloid Leukemia
NCT03573024Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2018
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by University of Colorado Denver. Primary endpoints: Response Rate at 4 years and Number of Participants That Achieved Minimal Residual Disease (MRD) Negative Responses at 4 years. Started Nov 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03573024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573024.